Literature DB >> 9454780

Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients.

S Nevo1, V Swan, C Enger, K J Wojno, R Bitton, M Shabooti, A K Fuller, R J Jones, H G Braine, G B Vogelsang.   

Abstract

Acute bleeding after bone marrow transplantation (BMT) was investigated in 1,402 patients receiving transplants at Johns Hopkins Hospital between January 1, 1986 and June 30, 1995. Bleeding categorization was based on daily scores of intensity used by the blood transfusion service. Moderate and severe episodes were analyzed for bleeding sites. Analysis of the cause of death and the interval of the bleeding episode to outcome endpoints was recorded. Survival estimates were computed for 1,353 BMT patients. The overall incidence was 34%. Minor bleeding was seen in 10.6%, moderate bleeding was seen in 11.3%, and severe bleeding was seen in 12% of all patients. Fourteen percent of patients had moderate or severe gastrointestinal hemorrhage, 6.4% had moderate or severe hemorrhagic cystitis, 2.8% had pulmonary hemorrhage, and 2% had intracranial hemorrhage. Sixty-one percent had 1 bleeding site and 34.4% had more than 1 site. Moderate and severe bleeding was more prevalent in allogeneic (31%) and unrelated patients (62.5%) compared with autologous patients (18.5%). Significant distribution of incidence was found among the different diagnoses, but not by disease status in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma. Bleeding was associated with significantly reduced survival in allogeneic, autologous, and unrelated BMT and in each disease category except multiple myeloma. Survival was correlated with the bleeding intensity, bleeding site, and the number of sites. Although close temporal association was evident to mortality, bleeding was recorded as the cause of death in only the minority of cases compared with other toxicities after BMT (graft-versus-host disease, infections, and preparative regimen toxicity). Acute bleeding is a common complication after BMT that is profoundly associated with morbidity and mortality. Although bleeding was not a direct cause of death in the majority of cases, it has a potential prognostic implication as a predictor of poor outcome in clinical assessment of patients after BMT.

Entities:  

Mesh:

Year:  1998        PMID: 9454780

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Exfoliative esophagitis early after autologous peripheral blood stem cell transplantation.

Authors:  S Hashino; K Chiba; N Toyoshima; S Suzuki; M Kurosawa; M Musashi; M Asaka
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Bleeding Assessment Scale in Critically Ill Children (BASIC): Physician-Driven Diagnostic Criteria for Bleeding Severity.

Authors:  Marianne E Nellis; Marisa Tucci; Jacques Lacroix; Philip C Spinella; Kelly D Haque; Arabela Stock; Marie E Steiner; E Vincent S Faustino; Nicole D Zantek; Peter J Davis; Simon J Stanworth; Jill M Cholette; Robert I Parker; Pierre Demaret; Martin C J Kneyber; Robert T Russell; Paul A Stricker; Adam M Vogel; Ariane Willems; Cassandra D Josephson; Naomi L C Luban; Laura L Loftis; Stéphane Leteurtre; Christian F Stocker; Susan M Goobie; Oliver Karam
Journal:  Crit Care Med       Date:  2019-12       Impact factor: 7.598

3.  Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models.

Authors:  Xueyan Sun; Yan Su; Xiao Liu; Yuanyuan Zhang; Yun He; Wei Han; Qi Chen; Huan Chen; Yu Wang; Yifei Cheng; Fengqi Liu; Fengrong Wang; Yao Chen; Gaochao Zhang; Xiaodong Mo; Haixia Fu; Yuhong Chen; Jingzhi Wang; Xiaolu Zhu; Lanping Xu; Kaiyan Liu; Xiaojun Huang; Xiaohui Zhang
Journal:  Bone Marrow Transplant       Date:  2021-01-07       Impact factor: 5.483

4.  Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial.

Authors:  Yaqiong Tang; Jia Chen; Qifa Liu; Tiantian Chu; Tingting Pan; Jianying Liang; Xue Feng He; Feng Chen; Ting Yang; Xiao Ma; Xiaojin Wu; Shaoyan Hu; Xingyu Cao; Xiaohui Hu; Jiong Hu; Yuejun Liu; Jiaqian Qi; Yueping Shen; Changgeng Ruan; Yue Han; Depei Wu
Journal:  Blood Adv       Date:  2021-03-09

5.  Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.

Authors:  Sunil Bhat; Satya Prakash Yadav; Madasu Anjan; Veronique Dinand; Anupam Sachdeva
Journal:  Indian J Pediatr       Date:  2011-02-17       Impact factor: 1.967

6.  An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies.

Authors:  Nakisa Khorsand; Nic J G M Veeger; Reinier M van Hest; Paula F Ypma; Jeroen Heidt; Karina Meijer
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

Review 7.  Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation.

Authors:  Hande H Tuncer; Naveed Rana; Cannon Milani; Angela Darko; Samer A Al-Homsi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

8.  Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation.

Authors:  Baolin Tang; Lulu Huang; Huilan Liu; Siqi Cheng; Kaidi Song; Xuhan Zhang; Wen Yao; Lijuan Ning; Xiang Wan; Guangyu Sun; Yun Wu; Jiehui Cheng; Qi Long; Zimin Sun; Xiaoyu Zhu
Journal:  Blood Adv       Date:  2020-08-25

Review 9.  The polyomavirus puzzle: is host immune response beneficial in controlling BK virus after adult hematopoietic cell transplantion?

Authors:  G Satyanarayana; F M Marty; C S Tan
Journal:  Transpl Infect Dis       Date:  2014-05-19       Impact factor: 2.228

10.  Risk factors for polyoma virus nephropathy.

Authors:  Olivier Prince; Spasenija Savic; Michael Dickenmann; Jürg Steiger; Lukas Bubendorf; Michael J Mihatsch
Journal:  Nephrol Dial Transplant       Date:  2008-12-10       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.